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e.2013.10Abstract Background: Angiopoietin related growth factor (AGF) is a liver derived factor that
potently antagonizes obesity and insulin resistance (IR).
Aim: The objective of this work is to determine AGF serum levels and evaluate its relationship
with total testosterone (TT), calculated free testosterone (cFT), sex hormone binding globulin
(SHBG), insulin and IR in normal weight and obese men.
Subjects: A total of 60 men were included: twenty normal weight subjects with body mass index
(18.5–24.7 kg/m2) and 40 obese men with BMI (30–39.5 kg/m2).
Methods: Serum AGF was measured by enzyme linked immunosorbent assay. Serum TT, SHBG,
and insulin were analyzed by chemiluminescent immunoassay.
Results: Angiopoietin related growth factor was signiﬁcantly lower in the obese group as compared
with normal weight group. In all subjects, AGF correlated positively with TT and SHBG and neg-
atively with 2 h oral glucose tolerance test (OGTT) glucose and fatty liver index (FLI). In normal
weight group, AGF correlated positively with age, SHBG, fasting insulin, HOMA-IR, AST andted growth factor; FLI, fatty
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38 M. Mohasseb et al.ALT and negatively with BMI, TC and LDL-C. In the obese group, it correlated positively with
BMI and negatively with TG. Multiple linear regression analysis revealed that SHBG and fasting
glucose were positive predictors of AGF serum levels. In the total sample, SHBG correlated
negatively with BMI, fasting glucose, fasting insulin, HOMA-IR, FLI and positively with AGF,
QUICKI and HDL-C.
Conclusion: The present results revealed for the ﬁrst time an association between SHBG and AGF
serum levels. It could be suggested that they overlap to regulate metabolic homeostasis in normal
weight men and that the disturbed inter-relationship could contribute to the pathogenesis of insulin
resistance and obesity. Moreover, the observed relationship between SHBG and AGF in the present
study could clarify the unresolved controversies regarding speciﬁc mechanistic relationships
between SHBG abnormalities and abnormalities in glucose homeostasis.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Obesity – a condition of excess adipose tissue in the body –
is emerging as an important cause of adverse health
outcomes. It is a worldwide epidemic that continues to grow
at an alarming rate. It has been postulated that in addition
to increased food intake,1 defective biochemical pathways
involved in energy expenditure may contribute signiﬁcantly
to obesity.2
Angiopoietin-related growth factor (AGF), also known as
angiopoietin-like protein 6 (Angptl 6), is secreted
predominantly from the liver into the systemic circulation.
Data provide very compelling evidence that AGF is a powerful
modulator of energy metabolism and adiposity.3 In animal
experiments, AGF increased energy expenditure and improved
insulin sensitivity and lipid proﬁles.4,5 It has been proposed
that AGF stimulates fat burning in peripheral tissues through
the activation of p38 mitogen activated protein kinase
(MAPK) pathway and downstream effects on respiration
and gene expression linked to mitochondrial uncoupling and
energy expenditure.4 It was also reported that AGF suppresses
gluconeogenesis via the activation of phosphoinositide
3-kinase/Akt signaling cascades resulting in reduced transcrip-
tional activity of FOXO1, a key transcription factor of
glucose-6-phosphatase expression.5
Testosterone (T), the predominant sex hormone in men, is
an anabolic hormone with a wide range of beneﬁcial effects
on men’s health. Both animal and human studies suggest that
T has favorable effects on insulin sensitivity in the male.
Castration of male rats results in marked insulin resistance,
which is abolished by physiological T replacement.6 In men,
low T concentrations are associated with insulin resistance
and adiposity.7,8 In contrast, T administration to obese men
with low normal T levels was associated with an improvement
in insulin sensitivity.9
It is well known that androgen mediates its biological
functions by binding with a high afﬁnity to speciﬁc androgen
receptors, which are found in normal human liver, the main
site of AGF expression. These androgen receptors belong to
the family of nuclear receptors that act as transcription factors
regulating the expression of several genes.10 Moreover, SHBG
which binds tightly to T and regulates free sex hormone
bioavailability to target tissues has emerged as a stronger
correlate with insulin resistance.11,12 The plasma membranes
of various kinds of cells, including the liver, have been shown
to be capable of binding speciﬁcally and with a high afﬁnity toSHBG, mediating sex hormone signaling at the cell membrane
through SHBG receptors.13,14
2. Aim of the work
The aim of the present work is to determine AGF serum levels
and evaluate its potential relationships with TT, cFT, SHBG,
insulin and IR in normal weight and obese men.
3. Subjects
Sixty adult males, fromworking staff inMedical Research Insti-
tute and their relatives, age ranging between 38 and 60 years,
were enrolled in this study. All participants gave their approval
to participate in the study and a written consent was obtained
from each subject. The Ethics Committee of the Medical
Research Institute, Alexandria University, approved the study
protocol and all experimental procedures were in accordance
with the Helsinki Declaration of 1975, as revised in 1983.
All subjects were apparently healthy with no previous
diagnosis or evidence, upon physical examination, of hyperten-
sion (BP < 130/85 mmHg), cardiovascular disease, diabetes
mellitus, endocrine disorders, renal or liver impairment, and
were not using any medications or supplements.
According to theWHO criteria for deﬁnition of obesity on the
basis of body mass index (BMI), subjects with BMI (18.5–24.9)
were included in thenormalweight group (n= 20) and thosewith
BMI (30–39.9) were included in the obese group (n= 40).
4. Methods
All the studied participants were subjected to:
4.1. Anthropometric measurements
Body mass index (BMI) was calculated as weight in kilograms
divided by square of the height in meters (kg/m2). In addition,
waist and hip circumferences were measured and the waist to
hip ratio (WHR) was then calculated.
4.2. Laboratory investigations which included
4.2.1. Fasting and 2 h serum glucose concentrations after
ingestion of 75 g glucose solution were determined.
SHBG, AGF and IR in normal weight and obese men 39Subjects with impaired glucose tolerance (fasting
glucose >110 mg/dl and/or 2 h OGTT glucose
> 140 mg/dl) were excluded from the present work.
4.2.2. Complete lipid proﬁle (TC, HDL-C, LDL-C, and TG),
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT) and gamma glutamyl transpeptidase
(GGT) activities were measured. Analysis was
performed on the autoanalyzer Konelab 30i system
using reconstituted freeze dried forms of multianalyte
calibrators for the serum samples.
4.2.3. We evaluated the fatty liver condition with the
validated fatty liver index (FLI) derived from TG
levels, BMI, waist circumference, and GGT levels as
follows: exp[0.953 · ln(TG) + 0.139 · BMI + 0.718 ·
ln(GGT) + 0.053 · waist-15.745]/(1 + exp[0.953 · ln-
(TG)+ 0.139 · BMI+ 0.718 · ln(GGT)+ 0.053 ·waist-
15.745]) · 100.15
4.2.4. Fasting insulin, total testosterone, and SHBG were
analyzed by chemiluminescent immunoassays on an
IMMULITE 2000 auto analyzer.
4.2.5. Insulin resistance was estimated using the homeostatic
model assessment of insulin resistance (HOMA-IR).16
The equation used was: HOMA-IR = (fasting insulin
[lIU/ml] · fasting glucose [mmol/L])/22.5.
4.2.6. Insulin sensitivity was estimated using the quantitative
insulin sensitivity check index (QUICKI)17 using the
following equation: QUICKI = 1/[log (fasting insulin
(lIU/mL) + log (fasting glucose (mg/dL)].
4.2.7. Total testosteroneandSHBGlevelswereused to calculate
free testosterone levels.18 Free testosterone levels
(nmol/L) = ([a+pb]/c)/109 with a= SHBG
(nmol/L)  TT(nmol/L) + 23.43, b= a2+(4 · 23.43 ·
TT [nmol/L]) and c= 2 · 23.43 · 109 for a standard
average albumin concentration of 4.3 g/dl.Table 1 Clinical and metabolic variables of normal weight and obe
Variables Normal (n= 20)
Age (years) 41(39–60)
BMI (kg/m2) 21.5(18.5–24.7)
Waist circumference (cm) 86.15 ± 7.32
Waist-hip-ratio 0.89(0.79–1.2)
AGF (ng/ml) 631.13 ± 112.9
TT (nmol/L) 23.81 ± 7.32
cFT (nmol/L) 0.38 ± 0.13
SHBG (nmol/L) 50.7(22.2–136)
Fasting glucose (mg/dl) 90.85 ± 6.92
2 h OGTT glucose (mg/dl) 84.17 ± 10.52
Fasting insulin (lIU/ml) 5.05 ± 1.89
HOMA-IR 1.14 ± 0.47
QUICKI 0.38 ± 0.02
Total cholesterol (mg/dl) 169.65 ± 28.34
HDL-cholesterol (mg/dl) 45.2 ± 9.35
LDL-cholesterol (mg/dl) 106.6 ± 24.69
Triglyceride (mg/dl) 91.05 ± 52.97
AST (u/l) 23.75 ± 9.1
ALT (u/l) 18.95 ± 7.89
GGT (u/l) 21.95 ± 7.52
Fatty liver index 16.83(1.66 ± 41.46)
Data are shown as mean ± SD or median (range).
* P< 0.05.
** P< 0.01.4.2.8. Serum AGF concentration was measured by Enzyme-
Linked Immunosorbant assay using a commercially
available kit AG, AdiopGen Inc. Incheon, Korea
according to manufacturer’s instructions.
4.3. Statistical analysis
Statistical analysis was performed using SPSS software. Nor-
mality was assessed by the Kolmogorov–Smirnov test. Data
were described as (mean ± SD) or median (range). Differences
between groups were analyzed with unpaired Student’s t-test,
or Mann–Whitney U test for normally and non-normally dis-
tributed parameters, respectively. Pearson’s and Spearman
Rank correlation coefﬁcients were calculated to evaluate the
inter-variable associations. To adjust the effects of covariates
and identify independent relationships, multiple linear regres-
sion analysis was performed. Covariables were added to the
models either because they were identiﬁed as signiﬁcantly asso-
ciated with AGF or SHBG in this study, or because they had
been previously described as determinants for AGF or SHBG.
The predictors which caused multicolinearity problems were
omitted. Variables that were not normally distributed such
as age, SHBG, and FLI, were log-transformed to approximate
normal distributions. A value of P< 0.05 was considered as
statistically signiﬁcant for all analyses.5. Results
The clinical and metabolic variables of normal weight (n= 20)
and obese groups (n= 40) are shown in Table 1. Obese men
had signiﬁcantly higher anthropometric indices (BMI, waist
circumference, and WHR), fasting and 2 h OGTT glucose,se groups.
Obese (n= 40) P value
43.5(38–57) 0.147
32.6(30–39.5) <0.001**
110.95 ± 6.08 <0.001**
0.92(0.77–1.34) <0.001**
464.55 ± 126.68 <0.001**
15.17 ± 3.87 <0.001**
0.35±.09 0.38
26.2(11.8–42.2) <0.001**
96.82 ± 9.65 0.017*
101.62 ± 15.9 <0.001**
10.97 ± 5.6 <0.001**
2.62 ± 1.35 <0.001**
0.33 ± 0.02 <0.001**
206.35 ± 33.51 <0.001**
39.98 ± 7.21 0.02*
143 ± 33.54 <0.001**
125.68 ± 44.8 <0.01*
24.08 ± 7.81 0.88
31.12 ± 11.76 <0.001**
32.7 ± 13 <0.001**
83.82(53.63 ± 97.44) <0.001**
40 M. Mohasseb et al.fasting insulin, HOMA-IR, lipid proﬁle (TC, LDL-C and TG)
and liver parameters (ALT, GGT and FLI) than those of nor-
mal weight men. Serum levels of AGF, TT, SHBG, QUICKI
and HDL-C were signiﬁcantly lower in the obese group as
compared with normal weight group. No signiﬁcant differ-
ences among the normal weight and obese group as regard
age, cFT and AST were detected. The correlations between
serum AGF levels and other clinical and metabolic variables
are shown in Table 2. When all subjects were considered for
analysis (n= 60), AGF serum levels correlated positively with
TT and SHBG and negatively with BMI, waist circumference,
WHR, 2 h OGTT glucose, TC, LDL-C, TG, ALT and FLI. In
normal weight group (n= 20), AGF serum levels correlated
positively with age, SHBG, FI, HOMA-IR, AST and ALT,
and negatively with BMI, TC, LDL-C. In the obese group
(n= 40), AGF correlated positively with BMI and negatively
with TG. To determine factors affecting serum AGF levels,
multiple linear regression analysis was performed. The model
included AGF (as a dependent variable) and age, SHBG,
FG, FI, TC and TG (as independent variables). As shown in
Table 3, SHBG and fasting glucose were positive, while TC
and TG were negative predictors of AGF serum levels.
(R2 = 31.5, F= 5.51, P< 0.0005).
The correlations between serum TT, cFT and SHBG and
other clinical and metabolic variables, in all studied subjects
(n= 60), are shown in Table 4. Total testosterone correlated
positively with SHBG and both correlated positively with
AGF and QUICKI, and negatively with BMI, WC, FG, fast-
ing insulin, HOMA-IR, TC, LDL-C, and FLI. Sex hormone
binding globulin also correlated signiﬁcantly and positively
with HDL-C and negatively with ALT and GGT. As regards
cFT, no correlations were detected except a signiﬁcant positive
correlation with TT. Multiple linear regression analysis wasTable 2 Correlations between AGF serum levels and various param
Variables AGF
Total (n= 60)
Age (years) 0.036a/0.78
BMI (kg/m2) 0.347a/0.007**
Waist circumference (cm) 0.495/0.001**
Waist-hip-ratio 0.370a/0.004**
Total testosterone (nmol/L) 0.413/0.001**
cFT (nmol/L) 0.28/0.83
SHBG (nmol/L) 0.357a/0.005**
Fasting glucose (mg/dl) 0.028/0.83
2 h OGTT glucose (mg/dl) 0.335/0.009**
Fasting insulin (lIU/ml) 0.185/0.15
HOMA-IR 0.174/0.18
QUICKI 0.245/0.059
Total cholesterol (mg/dl) 0.434/0.001**
HDL-cholesterol (mg/dl) 0.026/0.84
LDL-cholesterol (mg/dl) 0.340/0.008**
Triglyceride (mg/ dl) 0.405/0.001**
AST (u/L) 0.094/0.47
ALT (u/L) 0.314/0.01*
GGT 0.199/0.13
FLI 0.443a/0.001**
Coefﬁcients (r) and P values are calculated using Pearson’ correlation.
a Spearman’s correlation analysis.
* P< 0.05.
** P< 0.01.performed to evaluate the degree to which age, fasting glucose,
fasting insulin, AGF, FLI and TG predicted SHBG. As shown
in Table 5, age was positive whereas fasting insulin and FLI
were negative predictors of SHBG serum levels (R2 = 54.4,
F= 12.74, P< 0.0005). In addition, FLI correlated positively
and signiﬁcantly with FI and HOMA-IR in both the normal
weight group, FI (rs = 0.532, P=0.01), HOMA-IR (rs = 0.594,
P= 0.006) and in obese group, FI (rs = 0.580, P< 0.001),
HOMA-IR (rs = 0.564, P< 0.001).
6. Discussion
Deposition of excess fatty acids into fat cells in the form of tri-
glycerides is the biochemical basis of obesity, thus any imbal-
ance in food intake and energy utilization may result in
obesity. This homeostasis is complex and is regulated by a
multitude of poorly understood metabolic and endocrine
factors.19
Angiopoietin-related growth factor is a liver derived
circulating factor that counteracts obesity and related insulin
resistance through increased energy expenditure.4 Both vis-
ceral and subcutaneous fat depots were signiﬁcantly increased
in AGF-deﬁcient mice, and sections of white adipose tissue
from these mice showed increased adipocyte size relative to
those from wild-type mice. Furthermore, a large amount of li-
pid accumulation in liver and skeletal muscle was observed in
AGF-deﬁcient mice. Whereas no increase was observed in dai-
ly food intake in AGF-deﬁcient mice compared with wild-type
mice, it was suggested that inactivation of AGF in vivo leads
to decreased energy expenditure and obesity.4
Human studies showed that serum AGF levels were
paradoxically higher in subjects with metabolic syndrome
and diabetes than in healthy groups.20,21 It has been suggestedeters in total, normal weight and obese groups.
Normal (n= 20) Obese (n= 40)
0.646a/0.03* 0.014a/0.93
0.569a/0.009** 0.34a/0.03*
0.249/0.29 0.086/0.59
0.053a/0.82 0.251a/0.12
0.397/0.08 0.104/0.52
0.117/0.62 0.014/0.93
0.447a/0.04* 0.13a/0.43
0.086/0.72 0.205/0.2
0.018/0.94 0.113/0.48
0.485/0.03* 0.091/0.57
0.472/0.036* 0.012/0.46
0.388/0.09 0.081/0.62
0.473/0.03* 0.143/0.37
0.212/0.37 0.155/0.34
0.468/0.03* 0.02/0.9
0.066/0.78 0.469/0.002**
0.467/0.038* 0.047/0.77
0.472/0.036* 0.229/0.15
0.078/0.74 0.2/0.91
0.211a/0.37 0.077a/0.64
Table 3 Multiple linear regression analysis with serum AGF levels as dependent variable. (R2 = 31.5, P< 0.0005).
Independent variables Unstandardized coeﬃcients Standardized coeﬃcients t P value
B Std. error Beta
Age 254.539 391.409 .085 .650 .518
SHBG 240.352 97.148 .355 2.474 .017*
Fasting glucose 4.246 1.915 .270 2.217 .031*
Fasting insulin 3.195 3.487 .121 .916 .364
Total cholesterol 1.197 .496 .298 2.411 .019*
Triglyceride .982 .361 .339 2.717 .009**
* P< 0.05.
** P< 0.01.
Table 4 Correlations between TT, cFT and SHBG serum levels and various parameters (N= 60).
Variables TT cFT SHBG
Total testosterone (nmol/L) 1.000
cFT (nmol/L) 0.587/0.001** 1.000
SHBG (nmol/L) 0.646 a/0.001** 0.031a/0.81 1.000
Age (years) 0.03a/0.81 0.208a/0.11 0.100a/0.44
BMI (kg/m2) 0.595a/0.001** 0.211a/0.1 0.504a/0.001**
Waist circumference (cm) 0.579 /0.001** 0.111/0.4 0.487a/0.001**
Waist-hip-ratio 0.262a/0.04* 0.153a/0.24 0.23a/0.07
AGF(ng/ml) 0.413/0.001** 0.28/0.83 0.357a/0.005**
Fasting glucose (mg/dl) 0.262/0.04* 0.056/0.67 0.315a/0.01*
2 h OGTT glucose (mg/dl) 0.371/0.004** 0.148/0.26 0.233/0.07
Fasting insulin (lIU/ml) 0.368/0.004** 0.131/0.32 0.465a/0.001**
HOMA-IR 0.384/0.002** 0.135/0.3 0.498a/0.001**
QUICKI 0.44/0.001** 0.172/0.18 0.485a/0.001**
Total cholesterol (mg/dl) 0.475/0.001** 0.136/0.29 0.361a/0.005**
HDL-cholesterol (mg/dl) 0.052/0.69 0.14/0.28 0.265a/0.04*
LDL-cholesterol (mg/dl) 0.472/0.001** 0.145/0.27 0.368a/0.004**
Triglyceride (mg/dl) 0.055/0.67 0.145/0.27 0.236a/0.07
AST (u/L) 0.182/0.16 0.115/0.38 0.109a/0.4
ALT (u/L) 0.234/0.07 0.102/0.43 0.381a/0.003**
GGT 0.244/0.06 .002/0.98 0.460a/0.001**
FLI 0.482a/0.001** 0.049a/0.71 0.575a/0.001**
Coefﬁcients (r) and P values are calculated using Pearson’ correlation.
a Sperman’s correlation analysis.
* P< 0.05.
** P< 0.01.
Table 5 Multiple regression analysis with SHBG as dependent variable. (R2 = 54.4, P< 0.0005).
Independent variables Unstandardized coeﬃcients Standardized coeﬃcients t P value
B Std. error Beta
Age 1.583 .426 .358 3.714 .000**
Fasting glucose .004 .002 .163 1.625 .110
Fasting insulin .010 .004 .266 2.560 .013**
AGF .000 .000 .179 1.666 .102
Fatty liver index .232 .062 .500 3.771 .000**
Triglyceride .001 .000 .160 1.407 .165
** P< 0.01.
SHBG, AGF and IR in normal weight and obese men 41that the up regulation of AGF might be a compensatory
mechanism that partly limits hyperglycemia in humans.
In the present study, all participants had normal glucose
tolerance. Our results revealed that AGF serum levels andinsulin sensitivity index (QUICKI) were signiﬁcantly lower
while fasting insulin and HOMA-IR index were signiﬁcantly
higher in obese as compared to normal weight group. Further-
more, anthropometric indices (BMI, WC, and WHR) were
42 M. Mohasseb et al.signiﬁcantly higher in the obese group and correlated nega-
tively with AGF serum levels in all studied subjects. These
results conﬁrm the physiological role of circulating AGF
suggested in antagonizing obesity.4
Several studies indicate that skeletal muscle regulates en-
ergy expenditure, mediated by PPARs (PPARa, PPARd, and
PPAR!) and their coactivators (PGC-1a and PGC-1b) which
govern the expression of major enzymes of oxidative phos-
phorylation.22,23 Signiﬁcant decreases in the expression of the
genes encoding PPARd and PGC-1a in skeletal muscle in
AGF null mice, and increases in the expression of PPARa,
PPARd and PGC-1a in skeletal muscle of AGF transgenic
mice were indicated.4 It was stated that over expression of
AGF in vivo activates molecules involved in stimulating
energy expenditure, and thereby leads to decreased adiposity.
Moreover, Oike et al.4 also reported that AGF protein
enhances phosphorylation of p38 MAPK, which in turn,
improves the stability and activation of PGC-1a protein and
increase in energy expenditure.24
It should be noted that, in people who are not signiﬁcantly
physically active, 60–75% of total energy expenditure is con-
sumed as the resting metabolic rate (RMR), which can signif-
icantly affect weight gain or weight loss.25 In a study by
Mirzaei et al.26 they detected signiﬁcantly higher levels of
RMR/kg in subjects with higher circulating AGF concentra-
tion and conversely lower levels of RMR/kg in those with low-
er circulating AGF concentration in which 72.3% of them
were obese (BMIP 30).
In addition to its effect on energy expenditure, convincing
evidence has also presented that AGF potently antagonizes
insulin resistance. One mechanism whereby AGF affects insu-
lin sensitivity is inhibition of abnormal lipid stores in insulin
target tissues. It was found that even on a high fat diet,
AGF transgenic mice are protected against hepatic and muscle
steatosis resulting in the maintenance of insulin sensitivity.4 It
was reported that AGF activates p38 MAPK4 which plays a
critical role in lipid metabolism in the liver as it has an inhib-
itory role in hepatic lipogenesis.27 In humans, hepatic lipogen-
esis is strongly associated with fatty liver.28 This could explain
the signiﬁcantly higher FLI detected in the obese group which
correlated negatively with AGF serum levels and positively
with fasting insulin and HOMA-IR in all studied subjects.
Angiopoietin-related growth factor could also affect insulin
sensitivity by inhibiting gluconeogenesis. In an in vitro study
by Kitazawa et al.5, AGF was reported to suppress glucose
production in rat hepatocytes in a concentration dependent
manner through reduced expression of glucose-6-phosphatase.
This partially accounts for insulin sensitizing effect of AGF.
Thus a lower AGF serum level may suggest over expression
of glucose-6-phosphatase in liver which is sufﬁcient to perturb
whole glucose and lipid homeostasis.29 Our results revealed
that, fasting and 2 h OGTT glucose, TC, LDL-C and TG were
all signiﬁcantly higher while HDL-C was signiﬁcantly lower in
obese as compared to normal weight group. Moreover, signif-
icant negative correlations were detected between AGF serum
levels and 2 h OGTT glucose, TC, LDL-C and TG in the total
sample. These results are in accordance with those of Mirzaei
et al.26, who demonstrated signiﬁcant improvement of lipid
proﬁle in those with higher levels of AGF.
Contradictory to our results, Kadmatsu et al.3, found that
AGF serum levels are elevated in diet induced obese mice
and in obese humans; they considered that although thenormal production of AGF from liver may be up regulated
to counteract weight gain and promote insulin sensitivity, the
effect of AGF might also be attenuated in the obese state
and does not reverse obesity at all. Moreover, in diabetic pa-
tients21 AGF serum levels correlated positively with BMI
and the authors suggested that AGF antagonizes IR before
the onset of disease but is no longer an effective antagonist
after the disease is manifest. It was suggested that AGF
resistance may be attributed to decreased AGF sensitivity
and impaired receptor or post receptor signaling in its target
tissues.20,21
Interestingly, our results revealed that, AGF serum levels
signiﬁcantly and positively correlated with fasting insulin and
HOMA-IR in normal weight men. This up regulation of
AGF may be a physiological response to counteract insulin
resistance and compensate for disturbed metabolic proﬁle, pre-
vent weight gain and dyslipidemia as noticed by the signiﬁcant
negative correlations detected between AGF serum levels and
BMI, TC and LDL-C in normal weight men. This is in coinci-
dence with the signiﬁcant positive correlation detected in nor-
mal weight group between AGF serum levels and ALT, an
index of worsening of metabolic factors30 and an early marker
of insulin resistance.31 In the obese group, no such correlations
were detected; only TG serum levels correlated negatively with
AGF serum levels, while BMI correlated positively with AGF
suggesting disturbed physiological homeostasis, or a sort of
AGF resistance as previously suggested.20,21
In accordance with previous studies7,8,32, the present study
detected signiﬁcantly lower levels of TT and SHBG in the ob-
ese group as compared with normal weight group, and both
correlated positively with QUICKI and negatively with BMI,
WC, FG, and fasting insulin, HOMA-IR, TC and LDL-C.
Calculated FT, which serves as a stronger marker than TT
for androgen deﬁciency in males, showed no signiﬁcant differ-
ence between both groups and it correlated only with TT.
Total testosterone and SHBG both correlated positively and
signiﬁcantly with AGF serum levels. However no relationship
could be detected between cFT and AGF serum levels, suggest-
ing that SHBG may be the primary determinant of the appar-
ent relationship between TT and AGF. Multiple liner
regression analysis revealed that SHBG positively predicted
AGF serum levels suggesting that SHBG signaling may
regulate AGF expression in the liver and circulation.
The origin of low levels of TT in obese men is multifacto-
rial33, and attributed, in part, to decreased SHBG levels. The
low SHBG serum levels in obese individuals have been largely
attributed to hyperinsulinemia.34 Other investigators have sug-
gested that insulin suppression of SHBG is nonspeciﬁc and
probably reﬂects global reduction in hepatic protein secretion
under non-physiologic experimental conditions,35 this could
also explain the lower AGF serum levels detected in the obese
group. It was also suggested that excess monosaccharide con-
sumption and levels of fasting glucose rather than elevated
insulin levels are the actual determinants of liver SHBG
production.36,37 In addition, Selva et al.36, have previously
described the role of de novo lipogenesis in the down regulation
of hepatic SHBG expression, and a strong association between
fatty liver disease and low circulating SHBG levels has been
reported by Peter et al.37 This is in coincidence with our results
in which SHBG correlated negatively with FG, fasting insulin
and FLI. Moreover, those studies could explain the signiﬁcant
positive correlation detected in the present study between AGF
SHBG, AGF and IR in normal weight and obese men 43and SHBG serum levels, as it was previously mentioned that
AGF activates p38 MAPK4 which has an inhibitory role on
hepatic lipogenesis.27 In addition, multiple linear regression
analysis revealed that fasting insulin and FLI negatively pre-
dicted SHBG serum levels.
It was demonstrated that alterations in circulating levels of
SHBG appear to be associated with changes in glucose homeo-
stasis among individuals without diabetes,38 and that low
SHBG levels may precede the development of impaired glu-
cose metabolism.39 Moreover, lower SHBG levels predict met-
abolic syndrome40 and T2DM,
41 independent of serum
androgen levels, and the exact mechanism by which SHBG
inﬂuences metabolic components remains largely unclear.
The observed relationship between SHBG and AGF in the
present study could clarify the unresolved controversies
regarding speciﬁc mechanistic relationships between SHBG
abnormalities and abnormalities in glucose homeostasis.40,41
The small sample size is one of the limitations of the current
study. Also the cross-sectional design of the study makes inter-
pretation of the results limited. It does not allow clariﬁcation
of any cause-effect mechanism.7. Conclusion
The present results revealed for the ﬁrst time an association
between SHBG and AGF. Considering the ﬁndings of the
present study together with previous observations, it could
be suggested that SHBG and AGF may overlap to regulate
metabolic homeostasis and that the disturbed relationship be-
tween them could contribute to the pathogenesis of insulin
resistance and obesity. Prospective studies with large sample
identifying more in depth the relationship between SHBG
and AGF would be an important area for future research.
The beneﬁts of AGF administration in obese subjects are to
be deﬁned by large and long clinical trials.
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